Note 4. Intangible Assets
Goodwill
The Company has three reporting units: CooperVision and within the CooperSurgical segment, Office/Surgical and Fertility, reflecting the current way the Company manages its business. There was no impairment of goodwill in its reporting units in fiscal 2025, 2024, and 2023.
(In millions)CooperVisionCooperSurgicalTotal
Balance at October 31, 2024
$1,797.8 $2,040.6 $3,838.4 
Foreign currency translation adjustment12.2 2.8 15.0 
Balance at October 31, 2025
$1,810.0 $2,043.4 $3,853.4 
Of the October 31, 2025 goodwill balance, $282.2 million for CooperSurgical and $15.6 million for CooperVision is expected to be deductible for tax purposes. Of the October 31, 2024, goodwill balance, $311.5 million for CooperSurgical and $17.8 million for CooperVision was expected to be deductible for tax purposes.
Other Intangible Assets
 
October 31, 2025
October 31, 2024
(In millions)Gross
Carrying
Amount
Accumulated
Amortization
Gross
Carrying
Amount
Accumulated
Amortization
Weighted-average Amortization Period (in years)
Intangible assets with definite lives:
Customer relationships$1,137.6 $469.3 $1,130.5 $402.5 19
Composite intangible assets (1)
1,101.7 570.7 1,101.6 496.8 15
Technology683.4 415.3 706.4 384.3 11
Trademarks202.5 102.3 204.2 90.6 15
License and distribution rights and other44.5 26.9 47.9 27.2 11
3,169.7 $1,584.5 3,190.6 $1,401.4 16
Less: accumulated amortization and translation1,584.5 1,401.4 
Intangible assets with definite lives, net$1,585.2 $1,789.2 
Intangible assets with indefinite lives, net (2)
1.1 1.8 
Total other intangibles, net$1,586.3 $1,791.0 
(1) Composite intangible assets primarily consist of technology, trade name, New Drug Application approval and physician relationships. The components are not reflected separately or within the corresponding categories because they are inextricably linked.
(2) Intangible assets with indefinite lives include technology and trademarks.
Balances include foreign currency translation adjustments.
As of October 31, 2025, the estimate of future amortization expenses for intangible assets with definite lives is as follows:
Fiscal years:(In millions)
2026$188.9 
2027174.4 
2028169.8 
2029165.6 
2030161.4 
Thereafter725.1 
Total remaining amortization for intangible assets with definite lives$1,585.2 
The Company performed its annual impairment assessment in the third quarter of fiscal 2025 and concluded there was no material impairment to the Company's definite-lived or indefinite-lived intangible assets during fiscal 2025.
There was no material impairment to the Company's definite-lived or indefinite-lived intangible assets during fiscal 2024. In the fourth quarter of fiscal 2023, CooperVision fully impaired some intangible assets associated with the discontinuation of certain products. The carrying value of these intangible assets were immaterial.

Historical Timeline

Fiscal YearFiled
2025Dec 5, 2025Showing above
2021Dec 10, 2021

About Goodwill & Intangibles Disclosures

Goodwill and intangible asset disclosures reveal the premium paid in acquisitions and how management assesses whether that premium retains its value. Since goodwill is no longer amortized under US GAAP, the annual impairment test is the only mechanism that adjusts carrying values downward — making the assumptions behind that test critically important for investors.

Key signals: a history of goodwill impairments suggests management consistently overpays for acquisitions. Watch the gap between reporting unit fair value and carrying amount — when fair value exceeds carrying amount by less than 10-20%, a small decline in business performance could trigger a write-down. For finite-lived intangibles, examine useful life assumptions across customer relationships, technology, and trade names; aggressive estimates inflate near-term earnings. Compare total intangibles-to-total-assets ratios against peers to assess acquisition dependency. Rising goodwill as a percentage of equity can signal balance sheet fragility.